Related Experiment Video
Updated: Aug 13, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
Alf Spitschak1, Shailendra Gupta2, Krishna P Singh2
1Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, Germany.
Abstract:
Cancer cells have a remarkable ability to evade recognition and destruction by the immune system. At the same time, cancer has been associated with chronic inflammation, while certain autoimmune diseases predispose to the development of neoplasia. Although cancer immunotherapy has revolutionized antitumor treatment, immune-related toxicities and adverse events detract from the clinical utility of even the most advanced drugs, especially in patients with both, metastatic cancer and pre-existing autoimmune diseases. Here, the combination of multi-omics, data-driven computational approaches with the application of network concepts enables in-depth analyses of the dynamic links between cancer, autoimmune diseases, and drugs. In this review, we focus on molecular and epigenetic metastasis-related processes within cancer cells and the immune microenvironment. With melanoma as a model, we uncover vulnerabilities for drug development to control cancer progression and immune responses. Thereby, drug repurposing allows taking advantage of existing safety profiles and established pharmacokinetic properties of approved agents. These procedures promise faster access and optimal management for cancer treatment. Together, these approaches provide new disease-based and data-driven opportunities for the prediction and application of targeted and clinically used drugs at the interface of immune-mediated diseases and cancer towards next-generation immunotherapies.
Insights
This review explores the complex interplay between cancer, autoimmune diseases, and drug treatments. It identifies new therapeutic strategies by analyzing molecular and epigenetic processes, aiming to improve cancer immunotherapy outcomes.
Area of Science:
- Immunology
- Oncology
- Pharmacology
- Computational Biology
Background:
- Cancer cells evade immune detection, while inflammation and autoimmune diseases are linked to cancer development.
- Cancer immunotherapies face challenges with immune-related toxicities, particularly in patients with co-occurring metastatic cancer and autoimmune conditions.
- Understanding the dynamic links between cancer, autoimmunity, and drug effects is crucial for advancing treatment.
Purpose of the Study:
- To analyze the molecular and epigenetic links between cancer, autoimmune diseases, and drug actions using multi-omics and network approaches.
- To identify therapeutic vulnerabilities in cancer progression and immune responses, using melanoma as a model system.
- To explore drug repurposing for improved cancer treatment and management, especially for patients with immune-mediated diseases.
Main Methods:
- Utilizing multi-omics data and data-driven computational methods.
- Applying network concepts to analyze dynamic interactions between cancer, autoimmune diseases, and drugs.
- Focusing on molecular and epigenetic metastasis-related processes in cancer cells and the immune microenvironment.
- Employing melanoma as a model to uncover drug development vulnerabilities.
Main Results:
- Identification of molecular and epigenetic vulnerabilities in cancer progression and immune evasion.
- Demonstration of how network analysis can elucidate complex disease interrelationships.
- Highlighting the potential of drug repurposing for enhanced cancer therapy and patient management.
- Establishing a data-driven framework for predicting drug efficacy at the cancer-autoimmunity interface.
Conclusions:
- Integrated multi-omics and network analyses offer novel insights into the interplay of cancer and autoimmune diseases.
- Drug repurposing presents a viable strategy for developing safer and more effective cancer immunotherapies.
- This approach facilitates the prediction and application of targeted drugs for next-generation immunotherapies, benefiting patients with complex conditions.
